Continuous Process for PD-1 Therapy – KEYTRUDA®
Merck & Co. has developed a “continuous process” to produce KEYTRUDA® (pembrolizumab), an immunotherapy drug that increases the immune system to detect and fight tumor cells. In the new process developed by Merck, proteins are filtered away from the cells continuously rather than performing a one-time filtration step at the end of a batch.